Gilead’s Kite snares a landmark FDA OK on a $373,000 CAR-T therapy — which comes with bragging rights to the first true franchise op
While many of the top players in the immuno-oncology field have shifted their focus to new and better CAR-Ts in the pipeline, one of the pioneers in the field is now proudly laying claim to a landmark achievement — gaining a second OK and creating the first commercial CAR-T portfolio.
“We’re about to become the first company with a cell therapy franchise,” says Ken Takeshita, head of global development at Kite Therapeutics, a subsidiary of Gilead. The drug will be marketed as Tecartus and sold for $373,000, according to a company spokesperson on Friday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily — and it's free.